27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
- Amid data readouts from adagrasib, sitravatinib programs, Mirati Therapeutics Inc (NASDAQ:MRTX) has appointed David Meek as Chief Executive Officer, effective immediately.
- Related: Mirati Posts Adagrasib Data In KRAS-Mutated Lung Cancer, FDA Filing Now On The Cards.
- Mr. Meek will also join the Company's Board of Directors.
- Earlier CEO Charles Baum led the Company for nine years.
- Dr. Baum will continue to lead the research and development (R&D) organization as president, founder, and head of R&D and remain on the Company's Board of Directors.
- David Meek most recently served as president, CEO, and board member of FerGene.
- Related: Mirati Unveils Long-term Survival Data For Sitravatinib/Nivolumab Combo In Lung Cancer Patients.
- Price Action: MRTX stock is up 4.79% at $182.38 during the market session on the last check Monday.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!